L3VLUP
ProSign in

VRDN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VRDNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VRDN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterVRDNLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 20211 holders, $10m31 holders, $29.9bn
Q4 20212 holders, $7.3m31 holders, $34.7bn
Q1 20222 holders, $7.1m24 holders, $35.3bn
Q2 20222 holders, $8.5m33 holders, $42.7bn
Q3 20222 holders, $10.0m31 holders, $43.4bn
Q4 20225 holders, $38m31 holders, $46.6bn
Q1 20231 holders, $3.0m33 holders, $44.3bn
Q2 20232 holders, $8.9m37 holders, $59.6bn
Q3 20231 holders, $366k44 holders, $67.6bn
Q4 20231 holders, $51m45 holders, $73.6bn
Q1 20242 holders, $55m41 holders, $95.3bn
Q2 20242 holders, $48m43 holders, $110bn
Q3 20245 holders, $92m45 holders, $107bn
Q4 20243 holders, $68m46 holders, $93.9bn
Q1 20252 holders, $39m42 holders, $98.4bn
Q2 20252 holders, $43m43 holders, $93.2bn
Q3 20252 holders, $65m39 holders, $86.7bn
Q4 20254 holders, $89m41 holders, $123bn
Q1 20263 holders, $65m39 holders, $106bn
Q2 20263 holders, $70m44 holders, $132bn
VRDN

Viridian Therapeutics Inc

Holders
4
Reported value
$89m
Buyers
25
Sellers
4

Breadth +21 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 42 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VRDN (1)

Schonfeld Strategic Advisors LLC

Only LLY (38)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Millennium Management LLC, Neuberger Berman Group LLC, and 13 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →